Literature DB >> 1095495

Quantitation of human peripheral blood T and B lymphocytes.

T L Whiteside, R S Berardi, B S Rabin.   

Abstract

Centrifugation of heparinized peripheral blood on Ficoll-Hypaque under defined conditions is a most common method of lymphocyte purification in clinical studies. A loss of 25-30% of lymphocytes may occur during this procedure due to incomplete recovery of lymphocytes from the plasma layer after the gradient centrifugation and/or to poor recovery during the washing process. The loss is not selective since T and B cells are lost in the same proportions as determied by several different methods for T and B cell identification. Quantitation of T and B lymphocytes in terms of total number/mm-3 of peripheral blood is necessary in order to determine deficiencies in either of these two cell populations. The percentage values are inadequate in clinical evaluations. Thus, patients with chronic lymphocytic leukemia show elevated absolute number of T cells absolute numbers of T and B cells as well as percentages ought to be reported in all clinical studies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1095495     DOI: 10.1159/000231361

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

1.  T-cell and B-cell identification in the diagnosis of lymphoproliferative disease. A review.

Authors:  T L Whiteside; D T Rowlands
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

2.  Reactivity of anti-human brain serum with human lymphocytes.

Authors:  T L Whiteside
Journal:  Am J Pathol       Date:  1977-01       Impact factor: 4.307

3.  Localization of human T lymphocytes in tissue sections by a rosetting technique.

Authors:  D B Brubaker; T L Whiteside
Journal:  Am J Pathol       Date:  1977-08       Impact factor: 4.307

4.  Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma).

Authors:  H Kondo; B S Rabin; G P Rodnan
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.